Joele Frank is handling media for Alder BioPharmaceuticals, which is focused on the development and commercialization of migraine treatments, in its $2B sale to Denmark’s Lundbeck.
 |
The Danish company is offering $18 per-share for Alder, a 79 percent premium over its Sept. 13 closing price on the NASDAQ.
The owner of a portfolio of brain disease therapies will ante up another $2 per-share, if European regulators approve Alder’s next-generation eptinezumab migraine drug. The US Food & Drug Administration is on track to okay the treatment in February.
An estimated 135M people experience migraines annually. They are characterized by recurrent episodes of moderate to severe headaches accompanied by nausea, vomiting and sensitivity to sound and light.
CEO Deborah Dunsire called Alder an excellent strategic fit that leverages Lundbeck’s “specialized commercial expertise in delivering medicines for brain diseases.”
The transaction is expected to wrap up by yearend.
Joele Frank, Wilkinson Brimmer Katcher’s Andy Brimmer, Aura Reinhard and Tanner Kaufman represent Alder, while Stern Investor Relations’ Sarah McCabe works Wall Street for the Bothell, WA-based biopharmaceutical company.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
